Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...

We have been telling ourselves a story about pharma communications for the past 20 years. The story goes like this: Global ...

President Trump signs an executive order shrinking the recommended childhood vaccine schedule from 18 diseases to 11, and calls for the MMR shot to be split into three separate injections. President ...

In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva ...

Consideration includes $820 million upfront and up to $500 million in approval and sales milestones, with financing expected from cash on hand and existing credit facilities. ABS-1230 is a ...

In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...

Even products with a competitive advantage underperform three-year consensus targets 29% of the time; product superiority ...

Commercial Evidence aggregates compliant signals from in-person and digital engagement to reveal “why/why not” drivers of ...

Daniel Dornbusch (ddornbusch@mba2003.hbs.edu) leads the medical education team in Genentech?s Hematology Division. He previously worked for Genzyme, specializing in business, product, and corporate ...

Please check back later for more content.

FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...

The rumors of reported AstraZeneca–Bristol Myers merger discussions provide an opportunity to examine how multiple emerging capabilities may reshape corporate strategy, mergers and acquisitions, and ...